Holly Kramer, MD

Holly Kramer, MD, is a nephrologist at Loyola University Medical Center and the editor in chief of Advances in Kidney Disease and Health.

Articles by Holly Kramer, MD

Crisis Point: The Cause and Calamity, Neighborhood Disadvantage and Kidney Disease

ByMary K Roberts, PhD,Adrian Brown, PhD,Salvatore Viscomi, MD,Vahakn B Shahinian, MD,Holly Kramer, MD,Maya Clark Cutaia, PhD, RN,Tim Pflederer, MD

March 12th 2026

7 experts come together to address neighborhood disadvantage and its impact on kidney health in the latest Crisis Point.

1 Year After CKD Approval, Semaglutide Transforms Diabetes, Kidney, and Heart Care

ByDiana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Janani Rangaswami, MD, FAHA,Holly Kramer, MD,Vlado Perkovic, MBBS, PhD

February 20th 2026

1 year into real-world use, 4 clinicians discuss how semaglutide is transforming the endocrinology, nephrology, and cardiology landscape.

Obesity’s Double Role in CKD as Comorbidity and Driver

ByHolly Kramer, MD,Vlado Perkovic, MBBS, PhD

January 31st 2026

Obesity is common in CKD and drives hyperfiltration, nephron stress, and progressive kidney injury, according to experts, Kramer and Perkovic, and trial data.

Utilizing Diet to Prevent Obesity, Preserve Kidney Function, With Holly Kramer, MD

ByHolly Kramer, MD

January 30th 2026

Clinicians can provide dietitian intervention to reduce the risk of obesity, which is independently associated with CKD.

Holly Kramer, MD

Articles by Holly Kramer, MD

Crisis Point: The Cause and Calamity, Neighborhood Disadvantage and Kidney Disease

1 Year After CKD Approval, Semaglutide Transforms Diabetes, Kidney, and Heart Care

Obesity’s Double Role in CKD as Comorbidity and Driver

Utilizing Diet to Prevent Obesity, Preserve Kidney Function, With Holly Kramer, MD

Latest Updated Articles

Trending on HCPLive

Diagnostic Pearls and New Therapies in Connective Tissue Disease, With Michelle Min, MD

Rethinking “Type 2”: Inside the 2026 AACE Diabetes Classification Algorithm

VIASKIN Peanut Patch Efficacy Holds in Kids With Atopic Comorbidities

Fezolinetant Shows No CNS Safety Signal in Pooled Analysis of 3100 Women, With Marla Shapiro, CM

CAPTAIN-T2D: Interim Results Display High Cortisol Prevalence in Difficult-to-Control T2D